BiotechTube

Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease, Acromegaly

Trial Timeline

May 23, 2014 → Mar 26, 2018

NCT ID
NCT02060383

About Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin

Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin is a approved stage product being developed by Novartis for Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02060383. Target conditions include Cushing's Disease, Acromegaly.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02060383ApprovedCompleted

Competing Products

18 competing products in Cushing's Disease

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
52
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
77
Pasireotide sub-cutaneousNovartisPhase 3
77
osilodrostat + osilodrostat PlaceboNovartisPhase 3
77
OsilodrostatNovartisPhase 2
52
PasireotideNovartisPhase 3
77
SOM230 s.c.NovartisPhase 2
52
Lu AG13909LundbeckPhase 2
49
OsilodrostatRecordatiPre-clinical
20
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
82
osilodrostatRecordatiPhase 2
49
OsilodrostatRecordatiPre-clinical
20
mifepristoneCorcept TherapeuticsPhase 3
72
CORT125134Corcept TherapeuticsPhase 2
47
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
18
MifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85